Methods for diagnosis of myelodysplastic syndromes (mds)
AssigneeThe Trustees of the University of Pennsylvania
InventorsJonni MOORE, Sindhu Cherian, Adam Bagg
Life of this patent
Estimating the term…
Abstract
The present invention relates to methods and kits for diagnosing, ascertaining the clinical course of myelodysplastic syndrome (MDS) and ascertaining response to a therapy regimen of myelodysplastic syndrome. Specifically the invention provides methods and kits useful in the diagnosis and determination of clinical parameters associated with MDS based on surface markers unique to MDS.
Claims16
1-14. (canceled)
A method of quantifying the severity of myelodysplastic syndrome in a subject, comprising:
- obtaining a blood sample from the subject;
- measuring and analyzing predictive a set of predictive parameters in leukocytes from the blood sample of the subject using flow cytometry, wherein said set of predictive parameters comprises polymorphic neutrophil (PMN) granularity and leucocyte expression of CD66, CD11a, CD10, and CD116;
- assigning a numerical value to each predictive parameter;
- assigning a numerical score reflecting the predictive parameter values obtained for said leucocytes in said blood sample;
- comparing the predictive parameters to corresponding predictive parameters of a control sample;
- and assigning a numerical score reflecting predictive parameter values obtained for the control sample, wherein a score of 3 or greater indicates the severity of said myelodysplastic syndrome.
(canceled)
(canceled)
The method of claim 24, wherein said cell granularity is assessed by evaluating CD45 expression as a function of side scatter of said PMN.
(canceled)
29-55. (canceled)
Dependencies are inferred from the claim text.